Table 3.
Profile of efficacy in ipilimumab plus nivolumab.
| Characteristics | Total | Non-irAE group | irAE group | P value | |
|---|---|---|---|---|---|
| Non-severe irAE group |
Severe irAE group |
||||
| Total, n (%) | 161 (100) | 54 (33.5) | 48 (29.8) | 59 (36.7) | |
| Best response to ipilimumab plus nivolumab, n (%) | <0.05 | ||||
| Complete response | 17 (10.5) | 7 (13.0) | 3 (6.2) | 7 (11.9) | |
| Partial response | 55 (34.2) | 7 (13.0) | 21 (43.8) | 27 (45.8) | |
| Stable disease | 42 (26.1) | 15 (27.7) | 13 (27.1) | 14 (23.7) | |
| Progression disease | 37 (23.0) | 21 (38.9) | 8 (16.7) | 8 (13.5) | |
| Not evaluable | 10 (6.2) | 4 (7.4) | 3 (6.2) | 3 (5.1) | |
| Overall response rate (ORR), n (%) | <0.05 | ||||
| No | 79 (49.1) | 36 (66.7) | 21 (43.8) | 22 (37.3) | |
| Yes | 72 (44.7) | 14 (25.9) | 24 (50.0) | 34 (57.6) | |
| Not evaluable | 10 (6.2) | 4 (7.4) | 3 (6.2) | 3 (5.1) | |
| Disease control rate (DCR), n (%) | <0.05 | ||||
| No | 37 (23.0) | 21 (38.9) | 8 (16.7) | 8 (13.5) | |
| Yes | 114 (70.8) | 29 (53.7) | 37 (77.1) | 48 (81.4) | |
| Not evaluable | 10 (6.2) | 4 (7.4) | 3 (6.2) | 3 (5.1) | |